Evidence map›Paper›PMID 19244175›Full record

Trial reportJournal of the National Cancer Institute2009

Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer.

Dimitra Tsavachidou, Timothy J McDonnell, Sijin Wen, Xuemei Wang, Funda Vakar-Lopez, Louis L Pisters, Curtis A Pettaway, Christopher G Wood, Kim-Anh Do, Peter F Thall and 8 more

Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Journal of the National Cancer Institute, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Is There a Future for Chemoprevention of Prostate Cancer?Cancer prevention research (Philadelphia, Pa.) · 2016
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Nutrigenetics, nutrigenomics, and selenium.Frontiers in genetics · 2011
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Dimitra TsavachidouDepartment of Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Timothy J McDonnell
Sijin Wen
Xuemei Wang
Funda Vakar-Lopez
Louis L Pisters
Curtis A Pettaway
Christopher G Wood
Kim-Anh Do
Peter F Thall
Clifton Stephens
Eleni Efstathiou
Robert Taylor
David G Menter
Patricia Troncoso
Scott M Lippman
Christopher J Logothetis
Jeri Kim
Texas A&M University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Washington · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
University of Texas SPORE in Prostate CancerP50CA090270 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOGOTHETIS, CHRISTOPHER J. · 2001 to 2007
$13.6M
A FEASIBILITY STUDY OF L-SELENOMETHIONINE AND ALPHA-TOCOR21CA088761 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI KIM, JERI · 2000 to 2001
$561k
Differential Gene Expression Induced by AntioxidantsR03CA101072 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI KIM, JERI · 2003 to 2004
$151k
NCI NIH HHS P50 CA090270NCI NIH HHS P50 CA90270NCI NIH HHS R03 CA101072NCI NIH HHS R21 CA088761
6 · The paper itself

Abstract

backgroundSecondary analyses of two randomized, controlled phase III trials demonstrated that selenium and vitamin E could reduce prostate cancer incidence. To characterize pharmacodynamic and gene expression effects associated with use of selenium and vitamin E, we undertook a randomized, placebo-controlled phase IIA study of prostate cancer patients before prostatectomy and created a preoperative model for prostatectomy tissue interrogation.

methodsThirty-nine men with prostate cancer were randomly assigned to treatment with 200 microg of selenium, 400 IU of vitamin E, both, or placebo. Laser capture microdissection of prostatectomy biopsy specimens was used to isolate normal, stromal, and tumor cells. Gene expression in each cell type was studied with microarray analysis and validated with a real-time polymerase chain reaction (PCR) and immunohistochemistry. An analysis of variance model was fit to identify genes differentially expressed between treatments and cell types. A beta-uniform mixture model was used to analyze differential expression of genes and to assess the false discovery rate. All statistical tests were two-sided.

resultsThe highest numbers of differentially expressed genes by treatment were 1329 (63%) of 2109 genes in normal epithelial cells after selenium treatment, 1354 (66%) of 2051 genes in stromal cells after vitamin E treatment, and 329 (56%) of 587 genes in tumor cells after combination treatment (false discovery rate = 2%). Validation of 21 representative genes across all treatments and all cell types yielded Spearman correlation coefficients between the microarray analysis and the PCR validation ranging from 0.64 (95% confidence interval [CI] = 0.31 to 0.79) for the vitamin E group to 0.87 (95% CI = 0.53 to 0.99) for the selenium group. The increase in the mean percentage of p53-positive tumor cells in the selenium-treated group (26.3%), compared with that in the placebo-treated group (5%), showed borderline statistical significance (difference = 21.3%; 95% CI = 0.7 to 41.8; P = .051).

conclusionsWe have demonstrated the feasibility and efficiency of the preoperative model and its power as a hypothesis-generating engine. We have also identified cell type- and zone-specific tissue effects of interventions with selenium and vitamin E that may have clinical implications.

Indexed as

Gene Expression Regulation, NeoplasticGenetic MarkersAgedalpha-TocopherolAnalysis of VarianceAnticarcinogenic AgentsApoptosisBiomarkers, TumorCell ProliferationConfounding Factors, EpidemiologicDrug Therapy, CombinationFeasibility StudiesFollow-Up StudiesHumansImmunohistochemistryKi-67 Antigenalpha-TocopherolAnticarcinogenic AgentsBiomarkers, TumorGenetic MarkersKi-67 AntigenSelenomethionineTumor Suppressor Protein p53

Identifiers

PMID19244175
PMCPMC2734116
OpenAlexW2142340914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.